Abbott wins CE Mark for next-gen Xience Sierra drug-eluting stent

Abbott (NYSE:ABT) said today that it won CE Mark approval in the European Union for its next-generation drug-eluting stent, the Xience Sierra.

The everolimus-eluting coronary stent is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases, the Chicago-area healthcare giant said. If offers a thinner profile, increased flexibility, longer lengths and smaller diameters than previous stents.

Get the full story at our sister site, Drug Delivery Business News.

The post Abbott wins CE Mark for next-gen Xience Sierra drug-eluting stent appeared first on MassDevice.

from MassDevice http://ift.tt/2zYSJHY